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Abstract (number of words: 295) 
Background  
Symptomatic vertebral artery stenosis is associated with a high risk of recurrent stroke, with 
higher risks for intracranial than for extracranial stenosis. Vertebral artery stenosis can be 
treated with stenting with good technical results, but whether it results in improved outcome is 
uncertain. We performed an individual patient pooled analysis of completed randomised 




We analysed individual participant data from 354 individuals from three trials, including 179 
patients from VIST (148 extracranial, 31 intracranial), 115 patients from VAST (96 extracranial, 
19 intracranial), and 60 intracranial patients from SAMMPRIS (no extracranial). The primary 
outcome was any fatal or nonfatal stroke.  Cox regression analysis was performed stratified 
by trial.  
 
Findings 
168 subjects (46 intracranial; 122 extracranial) were randomised to medical treatment and 186 
to stenting (64 intracranial; 122 extracranial). In those randomised to stenting, the 
periprocedural stroke or death rate was higher for intracranial stenosis than for extracranial 
stenosis (10/64(15.6%) v 1/121(0.8%), p=0.00005). During 1,036 years of follow-up, the 
hazard ratio (HR) for any stroke in the stenting compared with the medical arm was 0.81 (95% 
confidence interval [CI] 0.45-1.44). For extracranial stenosis alone it was 0.63 (0.27-1.46), and 
for intracranial stenosis alone 1.06 (0.46-2.42). For patients randomised within 14 days of last 
symptoms HRs for any stroke were: all 0.65 (0.31-1.39), extracranial 0.56 (0.17-1.87), and 
intracranial 0.72 (0.27-1.90). 
 
Interpretation 
Stenting for vertebral stenosis has a much higher risk for intracranial, compared with 
extracranial, stenosis. This pooled analysis did not show a statistically significant benefit on 




intracranial stenosis. Stenting for extracranial stenosis might be beneficial, but further larger 





Research in context  
 
Evidence before this study  
Vertebral stenting has been widely used to treat symptomatic vertebral stenosis, but it is 
uncertain as to whether it reduces recurrent stroke rate. Randomised controlled trials 
comparing stenting with medical treatment were identified in the literature. A PubMed search 
was performed on 27th January 2018 using the search terms “vertebral artery AND stenting 
AND clinical trial”. We identified 3 trials of stenting versus medical therapy which included 
patients with symptomatic vertebral stenosis from which original participant data could be 
obtained. This included data from 354 individuals with 1,036 person-years of follow-up.  
 
Added value of this study  
Analysis showed that the peri-procedural risk of stroke and death was much higher for 
intracranial compared with extracranial stenosis (15.5 v 0.8%). There was no significant 
difference between either stenting or medical therapy alone in treatment in preventing stroke. 
There was no suggestion of any potential benefit for intracranial stenosis. For extracranial 
stenosis larger studies are required to determine whether there could be a benefit for stenting.  
 
Implications of all the available evidence 
Data from current randomised controlled trials, comparing medical treatment alone with 
stenting, for symptomatic vertebral stenosis shows no evidence that either treatment option is 
superior. Stenting of intracranial vertebral stenosis is associated with a high perioperative 
stroke risk, and is unlikely to be of benefit unless technological advances resulting in a lower 
stroke risk are developed. Stenting of extracranial stenosis is associated with a low 
perioperative stroke risk; further larger trials are required to determine whether it may confer 







20% of all acute ischaemic strokes are in the posterior (or vertebrobasilar) circulation.(1) In 
about a quarter of these the underlying pathophysiological mechanism is stenosis of the 
vertebral or basilar arteries.(1) Symptomatic vertebral stenosis is associated with a markedly 
increased risk of recurrent stroke, particularly in the first few weeks following symptoms.(2) It 
has been suggested that vertebral artery stenting may reduce this risk. A number of recent 
trials have examined this question, although all have been essentially phase 2 trials without 
sufficient sample size to definitively determine whether stenting is better than medical therapy.  
Interpretation of trial data is complicated by the differing natural history, and safety of stenting, 
for extracranial versus intracranial vertebral stenosis. Natural history studies have shown 
intracranial stenosis is associated with a higher risk of early recurrent stroke,(2) but it has also 
been associated with a higher periprocedural stroke risk with stenting.(3) In contrast, 
extracranial stenosis is associated with a lower but still elevated early recurrent stroke risk,(2) 
and a lower risk of periprocedural stroke.(3,4) Therefore, it is possible that the benefits of 
vertebral stenting differ for extracranial and intracranial vertebral stenosis.  
Studies in symptomatic carotid stenosis have shown that the benefit of intervention with 
revascularisation is highest in patients treated within the first two weeks following 
symptoms.(5) The temporal profile of increased stroke risk after symptomatic vertebral 
stenosis is very similar to that seen for carotid stenosis (2), and therefore it is possible that a 
similar enhanced benefit in patients treated soon after symptoms might also apply to vertebral 
stenosis. The results of the Vertebral artery Ischaemia Stenting Trial (VIST) supported this 
hypothesis, although because it was terminated early by the funder due to low recruitment, it 
was inadequately powered to definitively answer this question.(6)  
To determine whether vertebral stenting is more effective than medical treatment for 
symptomatic vertebral stenosis we performed an individual patient data pooled analysis of the 
vertebral artery stenting trials published to date. Because of the potential different treatment 
benefits in extracranial versus intracranial stenosis we also performed a pre-planned analysis 
in each subgroup. Additionally, we determined whether the benefit of stenting was increased 






Randomised control trials comparing stenting with medical treatment were identified in the 
literature. A PubMed search was performed on 27th January 2018 using the search terms 
“vertebral artery AND stenting AND clinical trial”. 45 papers were identified which included 
three trials. References and reviews were also searched identifying two further trials. In total 
five trials were identified: the Vertebral artery Ischaemia Stenting Trial (VIST)(6); the Vertebral 
Artery Stenting Trial (VAST) (7); the Stenting and Aggressive Medical Management for the 
Prevention of Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial (8); the Vitesse 
Intracranial Stent Study for Ischaemic Stroke Therapy (VISSIT)(9); and the Carotid and 
Vertebral Artery Transluminal Angioplasty Study (CAVATAS). (10) 
VIST and VAST included patients with both extracranial and intracranial stenosis. SAMMPRIS 
included patients with intracranial stenosis only at a variety of arterial locations: 60 participants 
were recruited for symptomatic vertebral stenosis. VISSIT randomised 112 patients with 
symptomatic intracranial stenosis in any artery, including the intracranial vertebral artery. The 
trial publication did not specify the number with vertebral stenosis and the trial investigators 
did not respond to emails enquiring about the number of vertebral artery cases and a data 
access request. Therefore, results of VISSIT could not be included in this analysis. CAVATAS 
recruited only 16 patients with vertebral stenosis; however, the primary intervention in the 
majority of cases was angioplasty rather than stenting, and patients were treated in the 1990s 
with a different generation of interventional devices and different medical regimens. For these 
reasons CAVATAS was not included in the pooled analysis.  
Individual patient data for VIST and VAST were obtained from the trial investigators, and 
individual patient data for SAMMPRIS were obtained from the National Institutes of Health 
(NIH) National Institute of Neurological Disorders and Stroke (NINDS) clinical trial data portal 
(https://clinicaltrials.gov/ct2/show/NCT00576693).  
There was no specific funding for this study 
 
Statistical analysis  
Data from the intention to treat analysis was used for all studies. The data from each trial were 
cleaned and harmonised to facilitate pooling across studies. We estimated hazard ratios with 
95% confidence intervals using Cox proportional-hazards regression models stratified by trial 
to compare outcomes in the stenting versus medical treatment arms. Each patient 




type, death, withdrawal, or loss of follow-up. Kaplan-Meier survival analysis was used to 
construct time-to-event curves, and the log-rank test was used to compare the cumulative 
number of events between groups. We also tested for interaction between the stenosis site 
and treatment arm. The primary outcome was any fatal or non-fatal stroke during follow-up. 
We also examined secondary outcomes for posterior circulation stroke, any stroke or TIA, 
stroke or death, and periprocedural stroke or death, which was defined as stroke or death 
within 30 days of randomisation. Analyses were performed for vertebral stenosis at any 
location and separately for extracranial and intracranial stenosis. As a sensitivity analysis we 
also repeated all analyses within the subset of the patients who were recruited within 14 days 
of symptom onset. Analyses were conducted using R version 3.4.4 (R Core Team) and Stata 
version 15.1 (StataCorp) with two-sided P-values and a significance level of P < 0.05. 
 
Results 
We analysed individual participant data from 354 individuals from three trials who were at risk 
for a total of 1,036 person-years. The study population consisted of 179 patients from VIST 
(148 extracranial stenosis, 31 intracranial), 115 patients from VAST (96 extracranial, 19 
intracranial), and 60 patients with intracranial stenosis from SAMMPRIS (no patients with 
extracranial stenosis were enrolled in this trial) (Figure 1, Supplementary Figure 1 and 
Supplementary Table 1). The mean (SD) age was 66 (10) years and 282 (80%) participants 
were male. A summary of other baseline characteristics by trial and treatment group is shown 
in Table 1.  
Mean (SD) time from last symptoms (TIA or stroke) to randomisation was 9.8 (7.4) days in 
SAMMPRIS, 36.4 (34.6) in VAST, and 36.0 (40.8) in VIST. The median follow-up time was 
36.5 months (5th–95th percentile: 3.4–64.2 months). The number of events for each outcome 
overall and by trial is shown in Table 2. Twenty-three (12.4%) of the 186 patients allocated to 
stenting and 24 (14.3%) of the 168 medically treated patients had a stroke. The resulting 
hazard ratio (HR) was 0.81 (95% confidence interval (CI) 0.45-1.44). For extracranial stenosis 
alone the HR was 0.63 (0.27-1.46), and for intracranial stenosis alone 1.06 (0.46-2.42). The 
P-value for the interaction of vertebral stenosis site with treatment arm was 0.395. 
Kaplan-Meier survival curves for the primary outcome are shown in Figure 2 for all stenoses 
(Figure 2a), extracranial stenosis (Figure 2b), and intracranial (Figure 2c). These show an 
initial high early stroke risk with stenting, largely reflecting a high periprocedural stroke or 




patients randomised to stenting was 1/121(0.8%) for extracranial stenosis, and 10/64(15.6%) 
for intracranial stenosis (chi-squared=16.3921; p<0.0001) (Figure 3). 
Results for stroke and TIA are shown in Table 3 and Figure 4. Results from the analyses of 
the other secondary outcomes are shown in Table 3 and Supplementary Figures 2-3. None of 
the analyses of secondary outcomes were statistically significant. 
Nearly half (n=161, 46%) of the 354 patients had a qualifying event that occurred within 14 
days of randomisation. Analyses of the primary outcome within this subset of patients are 
shown in the Supplementary Tables 2-4 and in Supplementary Figures 4-6, again for all 
stenosis and for extracranial and intracranial stenosis alone. The HRs were: 0.65 (0.31-1.39) 
for all stenoses, 0.56 (0.17-1.87) for extracranial stenosis, and 0.72 (0.27-1.90) for intracranial 
stenosis; interaction P-value = 0.77. 
Discussion 
This pooled analysis of individual patient data from completed vertebral artery stenting trials 
did not show a statistically significant benefit for either interventional or medical treatment in 
symptomatic vertebral stenosis. Consistent with previous data it confirmed a significantly 
higher periprocedural risk from intracranial compared with extracranial vertebral artery 
stenting.(3) Because of these different risks and benefits between intracranial and extracranial 
stenting we performed separate analyses for extracranial and intracranial stenoses. There 
was no evidence of benefit of either strategy for intracranial stenosis although confidence 
intervals around our effect estimates were wide. In contrast, we observed a trend towards 
benefit of stenting for extracranial stenosis, but this was not statistically significant and there 
was no significant interaction between the site of stenosis and longer-term outcome.  
Symptomatic intracranial stenosis has been associated with a high risk of early recurrent 
stroke. However, both SAMMPRIS and VISSIT, which both included patients with intracranial 
stenosis at a variety of locations in both the anterior and posterior circulations, reported that 
medical treatment was more effective than stenting, and that stenting was associated with a 
high risk of periprocedural stroke. SAMMPRIS instituted an intense medical antiplatelet 
treatment, and intense treatment of cardiovascular risk factors as well as lifestyle prevention 
measures. This was associated with a lower-than-expected recurrent stroke risk in the medical 
treatment arm. It is possible that the higher risk from stenting in intracranial stenosis may relate 
both to the much thinner wall of intracranial vessels leading to increased rupture risk, and also 
to the fact that perforating arteries arise from the intracranial vessels and that these arteries 




any difference in outcome between intracranial vertebral stenosis treated with either medical 
treatment or stenting. 
Stenting for extracranial vertebral stenosis has been associated with a much lower 
periprocedural stroke risk. Large series have found this to be in the order of 1%.(4) The results 
of our pooled analysis were consistent with this low risk. However, natural history studies have 
shown that while the risk of stroke on medical treatment alone is increased with extracranial 
stenosis, the absolute risk is lower than with intracranial stenosis.(2) Our pooled analysis 
showed no significant benefit for either stenting or medical treatment alone in this patient 
group. However, since the hazard ratio of any stroke for stenting was 0.63 (95% CI 0.27-1.46), 
our analysis is consistent with either substantial benefit or harm from stenting and larger trials 
are required to determine the benefit for stenting in extracranial stenosis.  
To determine the feasibility of further studies in extracranial and intracranial vertebral stenosis 
we determined the sample sizes required for a trial to show a difference between the two 
treatments using estimates of benefit from our current analysis. We used the risk of stroke 
during follow up in each group (extracranial stenting arm 9/122 (7.38%), medical arm  14/122 
(11.48%)), and intracranial, stenting arm 14/64 (21.88%)and medical arm 10/46 (21.74%), 
with power of 0.8 and significance of 0.05 and the ClinCalc online calculator  
(https://clincalc.com/stats/samplesize.aspx) The sample size required for to demonstrate an 
effect in extracranial stenosis would be 1592, but for intracranial stenosis would be 2731606.  
The risk of stroke after symptomatic minor stroke and TIA in carotid stenosis is highest in the 
first two weeks, and rapidly reduces after this time.(5) Natural history data from vertebral 
stenosis suggests a similar temporal profile.(2) A secondary analysis of the carotid 
endarterectomy trials showed that the benefit of surgery was much greater in those 
participants randomised within two weeks of symptoms(5). For this reason we performed a 
secondary analysis limited to those patients with symptomatic vertebral stenosis randomised 
within two weeks of symptoms. The results of this was similar to the overall analysis, again 
with a hazard ratio of any stroke of close to unity 0.72 for intracranial stenosis and a hazard 
ratio of 0.56 for extracranial stenosis.  
Strengths of our analysis are that we were able to include individual patient data allowing 
comprehensive assessment of benefits in the overall population and within subgroups. 
However it also has a number of limitations. We were unable to determine how many patients 
in the VISSIT trial had vertebral stenosis or obtain data on these patients. However, if the 
proportions of patients with vertebral stenosis are similar to that seen in SAMMPRIS we would 




therefore inclusion of these data is unlikely to have had a major effect on our results. Notably, 
the overall results from VISSIT were similar to those from SAMMPRIS. A potential limitation 
is the variety of medical therapy used in the different trials. In SAMMPRIS patients in the 
medical arm received intensive protocolised treatment. In VIST and VAST intensive medical 
therapy was recommended but not mandated. Unlike in SAMMPRIS, in which dual antiplatelet 
therapy and statins were mandated in the protocol, not all patients in VIST and VAST were on 
dual antiplatelet therapy with aspirin and clopidogrel, which has been suggested to be more 
effective at preventing embolisation in large-artery stroke (11) and recurrent events after 
stroke and TIA.(12,13) In VIST the proportion on dual antiplatelet treatment at one month was 
33% in the medical treatment arm and 57% in the stenting arm.(6) However, the use of statin 
treatment at one month follow-up (medical group 98%, stenting group 94%) and 
antihypertensive treatment (medical group 80%, stenting group 78%) was high in both 
treatment groups in VIST.  A further limitation is that even with inclusion of data from three 
studies the analysis was relatively underpowered; this partly resulted from premature 
termination of the VIST trial by the funder due to slow recruitment. 
Other considerations in interpretation and generalisability of the results are that SAMMPRIS 
included a high proportion of African Americans, while VIST and VAST had a predominantly 
white population, and that 80% of the participants in the pooled analysis were male, with only 
20% female. Furthermore, in VIST patient selection was based on non-invasive angiographic 
imaging and in 23 of 91 patients randomised to stenting there was no stenosis >50% stenosis 
at angiography performed prior to stenting. This could have led to an under-estimation of the 
risk associated with stenting. An additional consideration is that these studies examined 
stenting for usually first occurrence of first stroke or TIA. It has been suggested that recurrent 
stroke or TIA refractory to medical treatment might represent an indication for stenting, and it 
has been frequently performed for this indication, but we were unable to answer this question 
in this dataset. 
In conclusion, this pooled individual patient analysis of data from all available vertebral stenting 
trials provides the most comprehensive analysis currently possible of the effectiveness of 
vertebral stenting versus medical treatment in patients with recently symptomatic vertebral 
stenosis. We found no statistically significant difference between either treatment in preventing 
recurrent stroke. For intracranial stenosis the periprocedural risk of stenting was high, and 
there was no evidence of overall benefit on longer term follow-up. Based on these data further 
trials are unlikely to alter this conclusion unless the safety of intracranial stenting can be 
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(months) (5th & 
95th percentiles) 
Overall         
SAMMPRIS 60 64 (9) 49 (82) 37 (63) 146 (19) 25 (42) 18 (30) 32.8 (0.1 to 47.0) 
VAST 115 65 (10) 85 (74) 78 (68) - 19 (17) 33 (29) 36.4 (11.5 to 60.7) 
VIST 179 67 (10) 148 (83) 126 (70) 143 (60) 39 (22) 43 (24) 42.2 (3.4 to 71.4) 
Total 354 66 (10) 282 (80) 241 (68) 144 (52) 83 (23) 94 (27) 36.5 (3.4 to 64.2) 
         
Medical treatment group      
SAMMPRIS 22 64 (8) 18 (82) 17 (77) 149 (17) 7 (32) 11 (50) 34.3 (3.3 to 43.6) 
VAST 58 65 (10) 43 (74) 38 (66) - 12 (21) 14 (24) 36.2 (10.8 to 60.5) 
VIST 88 67 (10) 75 (85) 60 (68) 148 (83) 19 (22) 25 (28) 42.5 (3.4 to 69.5) 
Total 168 66 (10) 136 (81) 115 (68) 148 (74) 38 (23) 50 (30) 37.1 (4.9 to 63.3) 
         
Stenting/angioplasty treatment group      
SAMMPRIS 38 64 (10) 31 (82) 20 (54) 144 (20) 18 (47) 7 (18) 30.8 (0.1 to 48.0) 
VAST 57 65 (10) 42 (74) 40 (70) - 7 (12) 19 (34) 36.4 (12.0 to 61.3) 
VIST 91 68 (9) 73 (80) 66 (73) 138 (19) 20 (22) 18 (20) 41.6 (3.6 to 71.4) 
Total 186 66 (10) 146 (78) 126 (68) 140 (20) 45 (24) 44 (24) 36.4 (1.5 to 65.8) 
SBP, systolic blood pressure; SD standard deviation 
 
 





Number of events 












Any stroke or 
death within 
30 days 
Overall           
SAMMPRIS 60 4 (7%) 14 (23%) 11 (18%) 3 (5%) 9 (15%) 6 (10%) 18 (30%) 16 (27%) 7 (12%) 
VAST 115 NA 16 (14%) 14 (12%) 1 (1%) 9 (8%) 4 (3%) NA 18 (16%) 4 (3%) 
VIST 179 19 (11%) 17 (9%) 15 (8%) 0 (0%) 12 (7%) 17 (9%) 34 (19%) 30 (17%) 4 (2%) 
Total 354 23 (6%) 47 (13%) 40 (11%) 4 (1%) 30 (8%) 27 (8%) 52 (15%) 64 (18%) 15 (4%) 
           
Extracranial           
SAMMPRIS NA NA NA NA NA NA NA NA NA NA 
VAST 96 NA 12 (13%) 11 (11%) 1 (1%) 7 (7%) 2 (2%) NA 14 (15%) 2 (2%) 
VIST 148 18 (12%) 11 (7%) 11 (7%) 0 (0%) 6 (4%) 13 (9%) 28 (19%) 22 (15%) 2 (1%) 
Total 244 18 (7%) 23 (9%) 22 (9%) 1 (0%) 13 (5%) 15 (6%) 28 (11%) 36 (15%) 4 (2%) 
           
Intracranial           
SAMMPRIS 60 4 (7%) 14 (23%) 11 (18%) 3 (5%) 9 (15%) 6 (10%) 18 (30%) 16 (27%) 7 (12%) 
VAST 19 NA 4 (21%) 3 (16%) 0 (0%) 2 (11%) 2 (11%) NA 4 (21%) 2 (11%) 
VIST 31 1 (3%) 6 (19%) 4 (13%) 0 (0%) 6 (19%) 4 (13%) 6 (19%) 8 (26%) 2 (6%) 
Total 110 5 (5%) 24 (22%) 18 (16%) 3 (3%) 17 (15%) 12 (11%) 24 (22%) 28 (25%) 11 (10%) 
Note: All cases in SAMMPRIS had intracranial stenosis. VAST did not provide data on TIA outcomes so they were 










Table 3. Results of survival analyses: overall and by symptomatic artery 
 N No. of events (%) HR (95% CI) 
Any stroke    
All patients 354 47 (13%) 0.81 (0.45-1.44) 
Extracranial 244 23 (9%) 0.63 (0.27-1.46) 
Intracranial 110 24 (22%) 1.06 (0.46-2.42) 
    
Posterior circulation stroke    
All patients 354 30 (8%) 0.82 (0.40-1.70) 
Extracranial 244 13 (5%) 0.84 (0.28-2.49) 
Intracranial 110 17 (15%) 0.83 (0.31-2.19) 
    
Any stroke or TIA    
All patients 239 52 (22%) 0.68 (0.39-1.18) 
Extracranial 148 28 (19%) 0.52 (0.24-1.12) 
Intracranial 91 24 (26%) 0.92 (0.41-2.07) 
    
Any stroke or death    
All patients 354 64 (18%) 0.81 (0.49-1.33) 
Extracranial 244 36 (15%) 0.70 (0.36-1.35) 
Intracranial 110 28 (25%) 1.01 (0.47-2.16) 
    
Any stroke or death within 30 days of randomisation 
All patients 354 15 (4%) 2.20 (0.70-6.96) 
Extracranial 244 4 (2%) 0.33 (0.03-3.18) 
Intracranial 110 11 (10%) 7.46 (0.95-58.69) 





















451 patients with symptomatic 
intracranial stenosis were randomised 
Excluded 391 patients in 
SAMMPRIS without 
vertebral artery stenosis 
168 assigned to medical treatment alone 
- SAMMPRIS: 22 (0 extracranial, 22 intracranial) 
- VAST: 58 (48 extracranial, 10 intracranial) 
- VIST: 88 (74 extracranial, 14 intracranial) 
 
3 patients in VIST 
withdrew consent to 
randomisation assignment 
 
186 assigned to medical treatment plus stenting/angioplasty 
- SAMMPRIS: 38 (0 extracranial, 38 intracranial) 
- VAST: 57 (48 extracranial, 9 intracranial) 
- VIST: 91 (74 extracranial, 17 intracranial) 
 
Censored 4 patients in SAMMPRIS*: 
o 2 patients were lost to follow-up 
o 2 patients withdrew consent during 
study follow-up 
164 patients were followed-up until end of trial 
- SAMMPRIS: 18 
- VAST: 58 
- VIST: 88 
 
185 patients were followed-up until end of trial 
- SAMMPRIS: 37 
- VAST: 57 
- VIST: 91 
 
Censored 1 patient in SAMMPRIS*: 
o 1 patient was lost to follow-up 
VAST 
115 patients with vertebral artery 
stenosis were randomised 
VIST 
182 patients with vertebral artery 





Figure 2. Kaplan-Meier survival curves for cumulative probability of any stroke  
(a) All stenoses, (b) Extracranial stenosis, (c) Intracranial stenosis. Note: SAMMPRIS was excluded 









Figure 3. Kaplan-Meier survival curves for cumulative probability of periprocedural stroke or death 
(a) All stenoses, (b) Extracranial stenosis, (c) Intracranial stenosis. Note: SAMMPRIS was excluded 









Figure 4. Kaplan-Meier survival curves for cumulative probability of stroke or TIA by territory 
 (a) All stenoses, (b) Extracranial stenosis, (c) Intracranial stenosis. Note: VAST was excluded from all 
analyses of stroke or TIA because data on the outcome TIA were unavailable for VAST. Additionally, 
SAMMPRIS was excluded from analysis of extracranial stenosis as there were no patients in 
SAMMPRIS with extracranial stenosis.  
 
 
 
 
 
 
 
